AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Rated “Moderate Buy” by Wall Street Analysts

Posted by Jessica Moore on Oct 7th, 2026

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) have earned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $37.50.

A number of research analysts have issued reports on the company. Piper Sandler started coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target for the company. B. Riley Financial initiated coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Finally, Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating for the company.

View Our Latest Stock Report on AGMB

AgomAb Therapeutics Stock Up 1.7%

Shares of AGMB opened at $8.84 on Wednesday. The business’s 50-day moving average is $12.82 and its two-hundred day moving average is $12.00. AgomAb Therapeutics has a fifty-two week low of $7.97 and a fifty-two week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, analysts anticipate that AgomAb Therapeutics will post -1.76 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

(Get Free Report)

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.